Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience

Basit Öğe Kaydı
dc.contributor.authorCetin, Bulent
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorDane, Faysal
dc.contributor.authorBoruban, Cem
dc.contributor.authorGumus, Mahmut
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorKaplan, Mehmet A.
dc.date.accessioned2020-03-26T18:42:20Z
dc.date.available2020-03-26T18:42:20Z
dc.date.issued2013
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: The efficacy and safety of the lapatinib and capecitabine combination remain elusive in elderly patients with metastatic breast cancer (MBC), who progress after trastuzumab-based therapy. Patients and Methods: A total of 26 patients with HER2-positive MBC were included in this retrospective multicenter study. Median age was 69 years (range 65-82 years). All patients were treated with the combination of lapatinib (1,250 mg/day, continuously) and capecitabine (2,000 mg/m(2) on days 1-14 of a 21-day cycle). Data on demographics, clinical outcome, and toxicity were collected for descriptive analyses. Results: The median follow-up was 10 months (range 2-31 months). An overall response rate of 33.4% was achieved, including 1 complete response (3.8%), and 8 partial responses (30.8%). Median progression-free survival was 7 months (95% confidence interval (CI) 5-8), and the median overall survival was 15 months (95% CI 11-19). Most common side effects were fatigue (53.8%), diarrhea (46%), vomiting (36.3%), hand-foot syndrome (34.5%), and anorexia (34.6%). Grade 3-4 toxicities were identified as hand-foot syndrome (3.8%), diarrhea (7.6%), and fatigue (11.5%). There were no symptomatic cardiac events. Conclusion: Lapatinib and capecitabine combination therapy was effective and well tolerated in elderly patients with MBC, who had progressive disease after trastuzunnab-based therapy.en_US
dc.identifier.doi10.1159/000346829en_US
dc.identifier.endpage70en_US
dc.identifier.issn1661-3791en_US
dc.identifier.issue1en_US
dc.identifier.pmid24715846en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage67en_US
dc.identifier.urihttps://dx.doi.org/10.1159/000346829
dc.identifier.urihttps://hdl.handle.net/20.500.12395/29606
dc.identifier.volume8en_US
dc.identifier.wosWOS:000316036200011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKARGERen_US
dc.relation.ispartofBREAST CAREen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAdvanced breast canceren_US
dc.subjectElderly womenen_US
dc.subjectLapatiniben_US
dc.subjectCapecitabineen_US
dc.subjectHER2en_US
dc.titleLapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu